Clinical Trial Update: Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial update of obatoclax, fludarabine, and rituximab in previously treated chronic lymphocytic leukemia; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia

Drugs mentioned

• Fludarabine (Fludarabine)
• Obatoclax (obatoclax mesylate)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Chronic Lymphocytic Leukemia, Leukemia | Phase 1 | Status: TERMINATED